Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00766337 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
A Phase 2 study, sponsored by Santen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00766337: Clinical Trial Phase 2 study, sponsored by Santen.
NCT00766337 is a Phase 2 study that was terminated before completion, run by Santen. The registered enrollment target is 62 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00766337, a Phase 2 study, was terminated before completion, sponsored by Santen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation in combination with Lucentis in patients with sub-foveal choroidal neovascularization secondary to age-related macular degeneration.
Interventions
- DRUG Sirolimus in combination with ranibizumab
- DRUG Placebo in combination with ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Why NCT00766337 stopped before completion
NCT00766337 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which Sirolimus in combination with ranibizumab is the first listed.
NCT00766337 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00766337 about?
NCT00766337 is a clinical study titled "Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration". The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation in combination with Lucentis in patients with sub-foveal choroidal neovascularization secondary to age-related macular degeneration.
What is the current status of trial NCT00766337?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2008-12. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00766337?
The interventions under investigation include: Sirolimus in combination with ranibizumab (DRUG), Placebo in combination with ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00766337?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00766337's enrollment target sits among peer trials
62 1016th of 2000 higher than 975 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia